Problems › Should We Enter a New Market? › Fintech
Market attractiveness is the easy half. Right to win is the half that decides the outcome. This page works through it for fintech companies specifically — including an unedited excerpt from a real analysis of a fintech.
Market attractiveness is the easy half. Right to win is the half that decides the outcome. Fintech companies carry a specific bind here — lending fixed the P&L and converts revenue worth a 7x multiple into revenue worth a 2x multiple. Until that is priced, blended take rate will keep moving for reasons nobody can attribute, and the debate about right to win will stay a matter of opinion.
New markets get evaluated on size and growth, both of which are knowable and neither of which predicts success. The predictive question is what you already have that transfers — a customer relationship, a distribution route, a cost position, a body of data — and what has to be built from nothing.
A market can be highly attractive and a bad idea for you specifically. The reverse is also true: a dull market where you have a structural advantage will usually outperform an exciting one where you start level with everyone.
The other discipline is a stated kill criterion before entry, because market entries are unusually good at consuming budget quietly for years on the argument that they are nearly there.
These three together are the signature. One on its own usually points somewhere else.
✓ The case rests mainly on market size and growth rate
✓ Nobody has written down what would make you stop
✓ The existing business is flat and the new market is being asked to fix it
The move that usually makes it worse. Entering because the core business has stalled, which takes management attention away from the problem that actually needs it.
It is for you if you run or finance a fintech and the case rests mainly on market size and growth rate. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a fintech. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Verrano Pay, a sample company profile used for testing rather than a customer — $84M net revenue, 28,000 merchants, $9.4B of payment volume.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Lift lending take-up from 14% to 22% while keeping charge-offs below 9.0% by leveraging the existing vertical integrations and $9.4B TPV dataset.
| Investment required | $2.8-3.4M total (no new equity) |
| Expected return | Incremental lending revenue of $8.4-11.2M annually at 70% contribution margin yields 2.1-2.8× cash-on-cash return within 24 months on the $3.4M investment |
| Revenue, year 1 | $92-96M FY2026 |
| Revenue, year 2 | $101-110M FY2027 |
| Revenue, year 3 | $118-130M FY2028 |
| Exit criteria | Strategy must be abandoned or pivoted if, within 12 months, (a) take-up has not reached 16% OR (b) charge-off has exceeded 8.7% for two consecutive quarters, OR (c) any one of the three platform partners terminates its integration agreement. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Market Entry & Expansion Strategy, one of 29 engagements the platform runs. For fintech companies it works through blended take rate, charge-off rate, contribution margin and CAC by channel, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
List what you already own that the new market values, and what a credible incumbent there owns that you do not. If the second list is longer and includes anything structural — distribution, regulation, data depth — entry is a build, not an extension.
Set the number before you start, and treat exceeding it as the kill criterion rather than as a reason to invest more. Most failed entries were never killed, only slowly starved.
Whichever reuses more of what you already have. Geography usually reuses the product and rebuilds distribution; a new segment usually reuses distribution and rebuilds the product. Whichever rebuild is smaller is the safer bet.
Materially, yes. Lending fixed the P&L and converts revenue worth a 7x multiple into revenue worth a 2x multiple — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are blended take rate, charge-off rate, contribution margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on blended take rate and charge-off rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.